Both studies indicate an interesting link between the epigenetic enzyme JMJD3 and PPARα at the crossroad of autophagy and β-oxidation in NAFLD, which could be targeted by epigenetic drugs. The gene discussed is KDM6B; the disease is metabolic dysfunction-associated steatotic liver disease.